Active	Status	Sponsor type	Region	Phase	Filter
3 Active 4 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
triciribine phosphate (PTX-200) / VioQuest, Prescient Therap
NCT02930109: A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute Leukemia Jul 2019 - Sep 2019 : From P1b portion of P1b/2 trial	Completed	1/2	33	US	PTX-200, Triciribine Phosphate Monohydrate, Cytarabine, Ara-C	Prescient Therapeutics, Ltd.	Acute Leukemia	10/23	03/24
PTX-100 / Prescient Therap
NCT06854653: A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL	Recruiting	2	115	Europe, US, RoW	PTX-100	Prescient Therapeutics, Ltd.	CTCL	01/28	06/28
PTX-100-PD-012017, NCT03900442: Phase 1 Study of PTX-100 in Patients With Advanced Malignancies With PTCL Expansion Cohort	Active, not recruiting	1	25	RoW	PTX-100	Prescient Therapeutics, Ltd.	Advanced Cancer, PTCL	07/25	07/25

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
triciribine phosphate (PTX-200) / VioQuest, Prescient Therap
NCT02930109: A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute Leukemia Jul 2019 - Sep 2019 : From P1b portion of P1b/2 trial	Completed	1/2	33	US	PTX-200, Triciribine Phosphate Monohydrate, Cytarabine, Ara-C	Prescient Therapeutics, Ltd.	Acute Leukemia	10/23	03/24
PTX-100 / Prescient Therap
NCT06854653: A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL	Recruiting	2	115	Europe, US, RoW	PTX-100	Prescient Therapeutics, Ltd.	CTCL	01/28	06/28
PTX-100-PD-012017, NCT03900442: Phase 1 Study of PTX-100 in Patients With Advanced Malignancies With PTCL Expansion Cohort	Active, not recruiting	1	25	RoW	PTX-100	Prescient Therapeutics, Ltd.	Advanced Cancer, PTCL	07/25	07/25